Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Thérèse Aurran-Schleinitz
Real-World Results of Ibrutinib in Relapsed/Refractory CLL in France: Early Results on a Large Series of 428 Patients
American Journal of Hematology
Hematology
Related publications
Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Ibrutinib for Relapsed / Refractory Cll: An Update of the Uk and Ireland Analysis of Outcomes in 315 Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Results of an Early Access Treatment Protocol of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma
Cancer
Cancer Research
Oncology
Results From the Safety Run-In Period of the Sympatico Study Evaluating Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Interim Results of OPAL, a Study of Tosedostat in Elderly Relapsed/Refractory AML.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Preliminary Results of Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
